This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through October 6, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
pharmaceuticals: Archive
REGN & Tessera Collaborate to Develop Gene-Editing Therapy for AATD
by Zacks Equity Research
Regeneron teams up with Tessera to advance TSRA-196, aiming to correct the genetic cause of AATD as preclinical data support its move toward trials.
REGNNegative Net Change RHHBYPositive Net Change ANIPNegative Net Change CRMDNegative Net Change
biotechnology biotechs medical pharmaceuticals
BHC Stock Up as Solta Acquires Shibo's Aesthetics Distribution Business
by Zacks Equity Research
BHC jumps 11% as Solta Medical acquires Wuhan Shibo Zhenmei, gaining full control of its China aesthetics distribution business.
FOLDNegative Net Change ANIPNegative Net Change CRMDNegative Net Change BHCNegative Net Change
biotechnology biotechs medical pharmaceuticals
LLY Lowers Prices of Zepbound Vials for Cash Buyers on DTC Website
by Zacks Equity Research
Eli Lilly trims Zepbound vial prices on LillyDirect, offering lower monthly costs for self-paying patients across multiple doses.
PFENegative Net Change NVONegative Net Change LLYNegative Net Change VKTXNegative Net Change
biotechs medical pharmaceuticals
Pfizer's Cancer Drugs Deliver Growth Amid Competitive Pressure
by Kinjel Shah
Pfizer's expanding oncology portfolio, rising sales of key therapies, and steady pipeline progress reinforce its long-term cancer strategy momentum.
AZNNegative Net Change BMYNegative Net Change PFENegative Net Change MRKNegative Net Change
pharmaceuticals
JNJ Gets EU Nod for Imaavy in Generalized Myasthenia Gravis
by Zacks Equity Research
J&J gains EU approval for Imaavy, the first FcRn blocker for adults and adolescents with generalized myasthenia gravis.
JNJPositive Net Change CRMDNegative Net Change ADMANegative Net Change ARQTNegative Net Change
pharmaceuticals
Vaccine Stocks Fall After FDA Plans to Impose Stricter Vaccine Rules
by Sundeep Ganoria
Shares of vaccine makers slide as an internal FDA memo on vaccine safety and plans for stricter rules spark broad pressure across the overall industry.
PFENegative Net Change MRNANegative Net Change NVAXNegative Net Change BNTXNegative Net Change PCVXNegative Net Change
biotechs messenger-rna pharmaceuticals vaccines
BMY Wins EC Nod for Label Expansion of CAR T Cell Therapy Breyanzi (Revised)
by Zacks Equity Research
Bristol Myers wins EC approval to expand Breyanzi's label, adding MCL patients to its growing roster of European CAR-T indications.
BMYNegative Net Change JNJPositive Net Change BAYRYPositive Net Change
biotechnology biotechs medical pharmaceuticals
ARCT Stock Plunges 59% in Three Months: Here's What You Need to Know
by Zacks Equity Research
Arcturus Therapeutics' stock slides 59%, primarily due to mixed interim results from the phase II study of its investigational inhaled cystic fibrosis therapy, ARCT-032.
ARCTNegative Net Change CRMDNegative Net Change ADMANegative Net Change ARQTNegative Net Change
biotechnology biotechs medical pharmaceuticals
REGN Gains 21.5% in a Month: Time to Buy, Sell or Hold the Stock?
by Zacks Equity Research
Regeneron's surge is driven by fresh Eylea HD and Libtayo approvals, even as competition and valuation pressures loom.
REGNNegative Net Change SNYNegative Net Change RHHBYPositive Net Change BAYRYPositive Net Change
biotechnology biotechs medical pharmaceuticals
VKTX Stock Rises 34% in Three Months: Here's What You Should Know
by Sundeep Ganoria
Viking Therapeutics' shares jump 34% as rapid VK2735 trial enrollment boosts optimism amid intensifying interest in obesity treatments.
PFENegative Net Change NVONegative Net Change LLYNegative Net Change VKTXNegative Net Change
biotechs medical pharmaceuticals
Take the Zacks Approach to Beat the Markets: MBX Biosciences, Garrett Motion & Monster Beverage in Focus
by Santanu Roy
MBX Biosciences' sharp rally highlights how Zacks' stock recommendations outpaced broader market gains across multiple portfolios.
UNHPositive Net Change JNJPositive Net Change PWRPositive Net Change STXNegative Net Change AXSNegative Net Change CACINegative Net Change CORNegative Net Change MNSTNegative Net Change COHRPositive Net Change NOBLNegative Net Change GTXNegative Net Change MBXPositive Net Change
auto-tires-trucks business-services computers construction consumer-staples insurance medical pharmaceuticals
JNJ's Oncology Momentum Builds as It Chases $50B Goal by 2030
by Kinjel Shah
JNJ's oncology sales surge on strong drug launches and pipeline momentum, raising the stakes for its ambitious $50B 2030 goal.
AZNNegative Net Change JNJPositive Net Change PFENegative Net Change MRKNegative Net Change
pharmaceuticals
Buy These 5 Best Value Stocks to Make the Most of P/B Ratio
by Kinjel Shah
Discover five low P/B picks like STNE that are undervalued and show solid growth potential based on value-focused filters.
AXSNegative Net Change GLDDPositive Net Change ENSPositive Net Change STNEPositive Net Change KROSNegative Net Change
computers construction insurance pharmaceuticals
Bristol Myers vs Gilead Sciences: Which Biotech Stock Is a Better Bet Now?
by Ekta Bagri
GILD's HIV strength, new approvals, and rising estimates set it apart as it edges past a challenged rival in growth prospects.
BMYNegative Net Change GILDNegative Net Change
biotechnology biotechs medical pharmaceuticals
Will Opdivo and Opdivo Qvantig Drive BMY's Top-Line Growth?
by Ekta Bagri
Bristol Myers strengthens its Opdivo franchise with rising demand and strong uptake of Qvantig, leveraging label expansions to sustain revenue growth.
RHHBYPositive Net Change BMYNegative Net Change MRKNegative Net Change
biotechnology biotechs medical pharmaceuticals
Novo Nordisk or Pfizer: Which Healthcare Giant Is the Better Bet?
by Ahan Chakraborty
PFE's oncology gains and obesity re-entry contrast with NVO's GLP-1 pressures in this in-depth comparison of two healthcare giants.
PFENegative Net Change NVONegative Net Change LLYNegative Net Change
biotechnology biotechs medical pharmaceuticals
Novo Nordisk Seeks Extra-Fast Nod From FDA for Higher Dose of Wegovy
by Zacks Equity Research
NVO seeks an expedited FDA review for a higher 7.2 mg dose of Wegovy after strong weight-loss results in its STEP UP study.
PFENegative Net Change NVONegative Net Change LLYNegative Net Change VKTXNegative Net Change
biotechs medical pharmaceuticals
AstraZeneca or Merck: Which Oncology Giant Has the Edge?
by Kinjel Shah
AZN and MRK boast major oncology strengths and expanding pipelines amid shifting market dynamics in this pharma matchup.
AZNNegative Net Change MRKNegative Net Change CDTXPositive Net Change SMMTNegative Net Change
pharmaceuticals
BEAM vs. NTLA: Which Gene Editing Stock Holds More Potential?
by Sundeep Ganoria
Beam's broad early-stage pipeline and recent study progress take center stage as investors weigh its potential against rival NTLA's prospects.
REGNNegative Net Change BEAMNegative Net Change NTLANegative Net Change
biotechs cell-therapy crispr gene-editing gene-therapy medical pharmaceuticals
Lilly's Moment: AI-Powered Pipeline Positions Shares to Surge in 2026
by Bryan Hayes
Eli Lilly's stock is surging amid a flurry of AI deals. Our proprietary Zacks Rank system confirms the trend.
LLYNegative Net Change
artificial-intelligence earnings investing large-cap medical oncology-screening pharmaceuticals smart-health
NVO Stock Up as Amycretin Shows Strong Weight Loss in Type 2 Diabetes
by Zacks Equity Research
Novo Nordisk jumps after phase II data show amycretin offers significant weight loss and HbA1c level reductions in type 2 diabetes patients.
PFENegative Net Change NVONegative Net Change LLYNegative Net Change VKTXNegative Net Change
pharmaceuticals
AbbVie and Pfizer: A Closer Look at Two Pharma Heavyweights
by Kinjel Shah
ABBV's surging immunology sales and smoother LOE path stand out as both drugmakers face a pivotal 2026.
PFENegative Net Change NVONegative Net Change LLYNegative Net Change ABBVNegative Net Change
pharmaceuticals
Will Soft Gardasil Demand Continue to Dampen Merck's Top Line?
by Kanishka Das
MRK faces steep Gardasil declines as China and Japan demand soften, putting pressure on its vaccine portfolio.
SNYNegative Net Change AZNNegative Net Change MRKNegative Net Change
pharmaceuticals
Kymera Trades Near 52-Week High: Time to Buy, Sell or Hold the Stock?
by Zacks Equity Research
KYMR hits a 52-week high as optimism builds around KT-621's progress and upcoming data in atopic dermatitis.
SNYNegative Net Change GILDNegative Net Change KYMRNegative Net Change
biotechnology biotechs medical pharmaceuticals
BMY Wins EC Nod for Label Expansion of CAR T Cell Therapy Breyanzi
by Zacks Equity Research
Bristol Myers wins EC approval to expand Breyanzi's label, adding MCL patients to its growing roster of European CAR-T indications.
BMYNegative Net Change JNJPositive Net Change BAYRYPositive Net Change
biotechnology biotechs medical pharmaceuticals